EGFR and non-small cell lung carcinoma: Several genetic mutations, such as EGFR, HER2, MET and fusion oncogenes involving anaplastic lymphoma kinase (ALK), ROS1 and RET, have been identified and validated as oncogenic drivers, able to determine the development and maintenance of specific subclasses of NSCLC [35, 36].